JOUNCE THERAPEUTICS, INC.
- Country
- 🇺🇸United States
- Ownership
- Public, Subsidiary
- Established
- 2013-01-01
- Employees
- 141
- Market Cap
- -
- Website
- http://www.jouncetx.com
Clinical Trials
10
Trial Phases
2 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (10 trials with phase data)• Click on a phase to view related trials
Study of JTX-8064, as Monotherapy and in Combination With a PD-1 Inhibitor, in Adult Subjects With Advanced Refractory Solid Tumors
- First Posted Date
- 2020-12-17
- Last Posted Date
- 2024-04-09
- Lead Sponsor
- Jounce Therapeutics, Inc.
- Target Recruit Count
- 190
- Registration Number
- NCT04669899
- Locations
- 🇺🇸
University of Alabama at Birmingham, Birmingham, Alabama, United States
🇺🇸Banner MD Anderson Cancer Center, Gilbert, Arizona, United States
🇺🇸Arizona Clinical Research Center, Tucson, Arizona, United States
Study of PD-1 Inhibitor JTX-4014 Alone and in Combination With Vopratelimab in Biomarker-selected Subjects With Metastatic NSCLC After One Prior Platinum-containing Regimen
- First Posted Date
- 2020-09-16
- Last Posted Date
- 2024-05-22
- Lead Sponsor
- Jounce Therapeutics, Inc.
- Target Recruit Count
- 69
- Registration Number
- NCT04549025
- Locations
- 🇧🇾
Minsk City Clinical Oncology Dispensary, Minsk, Belarus
🇧🇾N. N. Alexandrov National Cancer Centre, Minsk, Belarus
🇧🇦University Clinical Center of the Republic of Srpska, Banja Luka, Bosnia and Herzegovina
Vopratelimab (JTX-2011) Alone and in Combination With Anti-Programmed Cell Death Protein 1 (PD-1) or Anti-Cytotoxic T-Lymphocyte Antigen 4 (CTLA-4) in Subjects With Advanced and/or Refractory Solid Tumors
- First Posted Date
- 2020-03-24
- Last Posted Date
- 2024-05-30
- Lead Sponsor
- Jounce Therapeutics, Inc.
- Target Recruit Count
- 4
- Registration Number
- NCT04319224
- Locations
- 🇺🇸
Washington University School of Medicine, Saint Louis, Missouri, United States
🇺🇸The University of Texas - MD Anderson Cancer Center, Houston, Texas, United States
🇺🇸University of Virginia Health Systems, Charlottesville, Virginia, United States
Vopratelimab and a CTLA-4 Inhibitor in PD-1/PD-L1 Inhibitor Experienced Subjects With NSCLC or Urothelial Cancer
- First Posted Date
- 2019-06-18
- Last Posted Date
- 2022-09-10
- Lead Sponsor
- Jounce Therapeutics, Inc.
- Target Recruit Count
- 61
- Registration Number
- NCT03989362
- Locations
- 🇺🇸
Beverly Hills Cancer Center, Beverly Hills, California, United States
🇺🇸University of Southern California Medical Center, Los Angeles, California, United States
🇺🇸Christiana Care Health Services, Newark, Delaware, United States
Study of a PD-1 Inhibitor (JTX-4014) in Subjects With Solid Tumor Malignancies
- First Posted Date
- 2018-12-31
- Last Posted Date
- 2023-07-03
- Lead Sponsor
- Jounce Therapeutics, Inc.
- Target Recruit Count
- 18
- Registration Number
- NCT03790488
- Locations
- 🇺🇸
Sarah Cannon Research Institute at HealthONE, Denver, Colorado, United States
🇺🇸Florida Cancer Specialists - Sarasota Cattlemen, Sarasota, Florida, United States
🇺🇸START Midwest - Cancer & Hematology Centers of Western Michigan, Grand Rapids, Michigan, United States
- Prev
- 1
- 2
- Next